Letter to the editor: safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-03-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/3/e011909.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849340185835208704 |
|---|---|
| author | Bi-Cheng Wang |
| author_facet | Bi-Cheng Wang |
| author_sort | Bi-Cheng Wang |
| collection | DOAJ |
| format | Article |
| id | doaj-art-e1a8e7a5f1ee4bbca99564fb5bb21566 |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-e1a8e7a5f1ee4bbca99564fb5bb215662025-08-20T03:43:57ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262025-03-0113310.1136/jitc-2025-011909Letter to the editor: safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteriaBi-Cheng Wang0Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Chinahttps://jitc.bmj.com/content/13/3/e011909.full |
| spellingShingle | Bi-Cheng Wang Letter to the editor: safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria Journal for ImmunoTherapy of Cancer |
| title | Letter to the editor: safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria |
| title_full | Letter to the editor: safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria |
| title_fullStr | Letter to the editor: safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria |
| title_full_unstemmed | Letter to the editor: safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria |
| title_short | Letter to the editor: safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria |
| title_sort | letter to the editor safety and efficacy of pd 1 inhibitor sintilimab combined with transarterial chemoembolization as the initial treatment in patients with intermediate stage hepatocellular carcinoma beyond up to seven criteria |
| url | https://jitc.bmj.com/content/13/3/e011909.full |
| work_keys_str_mv | AT bichengwang lettertotheeditorsafetyandefficacyofpd1inhibitorsintilimabcombinedwithtransarterialchemoembolizationastheinitialtreatmentinpatientswithintermediatestagehepatocellularcarcinomabeyonduptosevencriteria |